In the News
Please find below a selection of recent media coverage in which the Emergex Vaccines story is featured.
European Pharmaceutical Review: Anatomy of a ‘correlate of protection’ for T-cell vaccines
16 June 2022
NanoPass’s intradermal delivery platform used in Emergex’s next generation COVID-19 vaccination study
26 January 2022
The Guardian – UK firm to trial T-cell Covid vaccine that could give longer immunity
15 November 2021
CNBC news interview with Emergex Vaccines CEO, Professor Thomas Rademacher
14 May 2018
